Ali Rizvi to Dipeptidyl-Peptidase IV Inhibitors
This is a "connection" page, showing publications Ali Rizvi has written about Dipeptidyl-Peptidase IV Inhibitors.
Connection Strength
2.363
-
Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections. Expert Opin Drug Saf. 2022 03; 21(3):291-293.
Score: 0.785
-
The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. Metabolism. 2020 08; 109:154295.
Score: 0.698
-
Incretin-based therapies, glucometabolic health and endovascular inflammation. Curr Pharm Des. 2014; 20(31):4953-60.
Score: 0.446
-
Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. Metabolism. 2020 10; 111:154343.
Score: 0.176
-
Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights. J Cardiovasc Pharmacol Ther. 2020 11; 25(6):494-496.
Score: 0.175
-
Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin Investig Drugs. 2009 Oct; 18(10):1495-503.
Score: 0.083